English

Interim report Q2, 2022: Together for successful growth

Report this content

Second quarter

  • Sales of SEK 829 (382) million, corresponding to an increase of 117% in SEK, whereof currency effect 18%, acquired growth 80% and organic growth 18%.
  • Consumables increased sales by 24% in SEK, Technologies by 37% in SEK, and Genetic Services contributed sales of SEK 341 million.
  • Strong growth in all market regions. Americas 241%, EMEA 53%, Japan Pacific 85% and Asia 73% in local currencies.
  • Operating income before depreciation and amortisation (EBITDA) was SEK 273 (134) million, corresponding to a margin of 32.9% (35.2%). EBITDA per share increased by 63%.
  • Net income was SEK 130 (86) million, resulting in earnings per share of SEK 0.96 (0.79).

Pro forma

  • Sales, adjusted for business related to Covid-19 tests, increased by 24% in SEK, and 14% in local currencies.
  • EBITDA margin of 32.9% (32.8%).

First half year

  • Sales of SEK 1,581 (761) million, corresponding to an increase of 108% in SEK, whereof currency effect 16%, acquired growth 77% and organic growth 15%.
  • Consumables increased sales by 25% in SEK, Technologies by 18% in SEK, and Genetic Services contributed sales of SEK 645 million.
  • Strong growth in all market regions. Americas 247%, EMEA 68%, Japan Pacific 48% and Asia 45% in local currencies.
  • Operating income before depreciation and amortisation (EBITDA) was SEK 501 (297) million, corresponding to a margin of 31.7% (39.1%). EBITDA per share increased 35%.
  • Net income was SEK 213 (205) million, resulting in earnings per share of SEK 1.56 (1.88).

Pro forma

  • Sales, adjusted for business related to Covid-19 tests, increased by 21% in SEK, and 12% in local currencies. 
  • EBITDA margin of 31.7% (33.6%).


Gothenburg, July 15, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, phone: +46 31 721 80 01
Patrik Tolf, CFO, phone: +46 31 766 90 21

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on July 15, 2022.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_____________________________________________________________________________________________________________________________________________________________

Vitrolife is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. Vitrolife is supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. Currently, we are approximately 1,150 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife’s products and services are available in more than 110 countries, through our own presence in 30 countries and a network of distributors. Vitrolife is a sustainable market leader and aims to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a baby. The Vitrolife share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Subscribe

Documents & Links